City

Langfang (1)

Salt Lake City (1)

Condition

High Risk Hematologic Malignancies (2)

Relapsed and/or Refractory Acute Myeloid Leukemia (1)

Overall Status

Not yet recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1 (2)

Sponsor

University of Utah (1)

iCell Gene Therapeutics (1)

Collaborator

iCar Bio Therapeutics (1)

Intervention

anti-cd33 car t cells (1)

stem cell transplant (1)

Study Documents

Intervention Type

biological (2)

procedure (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

high risk hematologic malignancies

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies Trial in Langfang (anti-CD33 CAR T cells)

Not yet recruiting

Relapsed and/or Refractory Acute Myeloid Leukemia
High Risk Hematologic Malignancies

anti-CD33 CAR T cells

Langfang, Hebei, China

Hebei Yanda Lu Daopei Hospital

Jun 30, 2022

High Risk Hematologic Malignancies Trial in Salt Lake City (stem cell transplant, Stem cell transplant)

Terminated

High Risk Hematologic Malignancies

stem cell transplant
Stem cell transplant

Salt Lake City, Utah

Huntsman Cancer Institute

Aug 10, 2020